108 related articles for article (PubMed ID: 3588172)
1. Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.
László FA; Baláspiri L
Acta Med Hung; 1986; 43(3):333-9. PubMed ID: 3588172
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate.
László FA; Csáti S; Baláspiri L
Acta Endocrinol (Copenh); 1984 May; 106(1):56-60. PubMed ID: 6730855
[TBL] [Abstract][Full Text] [Related]
3. Effect of the vasopressin antagonist d(CH2)5 Tyr(Et)VAVP on diuresis in rat.
László FA; Csáti S; Baláspiri L; Manning M
Acta Med Hung; 1984; 41(1):65-73. PubMed ID: 6739224
[TBL] [Abstract][Full Text] [Related]
4. [The effect of vasopressin analogs on water metabolism].
László F; Laczi F; Julesz J; Baláspiri L
Z Gesamte Inn Med; 1983 Nov; 38(22):248-50. PubMed ID: 6666181
[TBL] [Abstract][Full Text] [Related]
5. Effect of the vasopressin antagonist d/CH2/5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin.
László FA; Csáti S; Baláspiri L
Acta Endocrinol (Copenh); 1984 May; 106(1):52-5. PubMed ID: 6730854
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder.
Mann WA; Stassen F; Huffman W; Kinter LB
J Pharmacol Exp Ther; 1986 Aug; 238(2):401-6. PubMed ID: 3090234
[TBL] [Abstract][Full Text] [Related]
7. [Schwartz-Bartter syndrome following long-term DDAVP therapy in a patient with diabetes insipidus].
Radó J; Pató E
Orv Hetil; 1983 May; 124(22):1323-6. PubMed ID: 6877810
[No Abstract] [Full Text] [Related]
8. Effect of vasopressin antagonist d(CH2)5Tyr(Et)VAVP on plasma arginine vasopressin level after osmotic stimulus.
László FA; Laczi F; Janáky T; Baláspiri L
Endocr Regul; 1991 Sep; 25(3):181-3. PubMed ID: 1764609
[TBL] [Abstract][Full Text] [Related]
9. Development of the Schwartz-Bartter syndrome after the administration of chlorpropamide and 1-deamino-8-D-arginine vasopressin.
Valkusz Z; Laczi F; László FA
Endokrinologie; 1982 Jul; 79(3):345-8. PubMed ID: 7128548
[No Abstract] [Full Text] [Related]
10. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
11. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
12. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin.
Ishikawa S; Kim JK; Schrier RW
Am J Physiol; 1983 Nov; 245(5 Pt 1):R713-9. PubMed ID: 6688929
[TBL] [Abstract][Full Text] [Related]
13. [Development of Schwartz-Bartter syndrome following administration of chlorpropamide and 1-deamino-8-D-arginine vasopressin].
Valkusz Z; Laczi F; László F
Orv Hetil; 1981 Jan; 122(2):97-8. PubMed ID: 7231991
[No Abstract] [Full Text] [Related]
14. Prevention of cerebral edema by the vasopressin antagonist d(CH2)5D-Ile2Ile4Ala9AVP in rats with experimental subarachnoid hemorrhage.
László FA; Varga C; Baláspiri L
Ann N Y Acad Sci; 1993 Jul; 689():627-9. PubMed ID: 8373062
[No Abstract] [Full Text] [Related]
15. Desensitization of renal vasopressin-stimulated adenylate cyclase by a vasopressor and antidiuretic antagonist, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-ethyl)-D-tyrosine, 4-valine]arginine vasopressin.
Chang P; Kimura K
Biochem Biophys Res Commun; 1987 Apr; 144(2):770-8. PubMed ID: 3579941
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and receptor specificities of vasopressin antagonists.
Manning M; Sawyer WH
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S29-35. PubMed ID: 2434768
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus).
Kinter LB; Churchill S; Stassen FL; Moore M; Huffman W
J Pharmacol Exp Ther; 1987 Jun; 241(3):797-803. PubMed ID: 3598903
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats.
Mah SC; Hofbauer KG
J Pharmacol Exp Ther; 1988 Jun; 245(3):1028-32. PubMed ID: 2968448
[TBL] [Abstract][Full Text] [Related]
19. Normal acid-base equilibrium in acute hyponatremia and mixed alkalosis in chronic hyponatremia induced by arginine vasopressin or 1-deamino-8-D-arginine vasopressin in rats.
Decaux G; Crenier L; Namias B; Gervy C; Soupart A
J Lab Clin Med; 1994 Jun; 123(6):892-8. PubMed ID: 8201268
[TBL] [Abstract][Full Text] [Related]
20. The effects of subcutaneous administration of arginine-8-vasopressin on the electroencephalogram of conscious rats are mediated by peripheral vasopressin V1 receptors.
Ebenezer IS
Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):315-21. PubMed ID: 7934310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
